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Abstract
Gastroesophageal reflux (GER), defined as the passage of gastric contents into the 
esophagus, is a normal physiologic process occurring several times per day in healthy 
infants, children, and adults. The majority of GER episodes occur in the postprandial 
period, last in <3 min, and cause few or no symptoms. Conversely, when the reflux 
of gastric contents into the esophagus causes troublesome symptoms and/or com-
plications, we talk about “gastroesophageal reflux disease (GERD).” Distinguishing 
physiologic GER from GERD may often be tricky for clinicians, especially in infants. 
The typical presentation of GERD includes the following symptoms: recurrent regur-
gitation, vomiting, weight loss or poor weight gain, excessive crying and irritability in 
infants, heartburn or chest pain, ruminative behavior, hematemesis, and dysphagia. 
Besides these esophageal symptoms, there is a set of extra-esophageal symptoms, 
mainly respiratory, which may occur along with typical symptoms or may represent 
the only clinical picture of GERD: odynophagia, wheezing, stridor, cough, hoarse-
ness, dental erosions, and apnea/apparent life-threatening events (ALTEs). While 
infantile GER tends to resolve spontaneously and does not deserve pharmacological 
treatment, GERD management includes lifestyle changes, pharmacologic therapy, 
and surgery. Therefore, a proper diagnosis of these two conditions, besides other pos-
sible conditions mimicking reflux, is crucial in order to target the treatment, avoiding 
the overuse of antacid drugs that currently represents a major source of concern.
Keywords: gastroesophageal reflux, gastroesophageal reflux disease, vomiting, 
regurgitation, heartburn, irritability, chest pain, respiratory symptoms,  
typical GERD presentation, atypical GERD presentation
1. Introduction
Gastroesophageal reflux (GER) is a normal physiologic process occurring several 
times per day in healthy infants, children, and adults. Most episodes of GER in 
healthy individuals occur in the postprandial period, last in <3 min, and cause few 
or no symptoms [1]. In contrast, according to the clinical practice guidelines for 
the diagnosis and management of reflux in the pediatric population, published 
by the North American Society for Pediatric Gastroenterology, Hepatology, and 
Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, 
Hepatology, and Nutrition (ESPGHAN), gastroesophageal reflux disease (GERD) is 
present when the reflux of gastric contents into the esophagus causes troublesome 
symptoms and/or complications [2]. Reflux symptoms may vary widely according 
to age. Therefore, distinguishing physiologic GER from GERD may often be tricky, 
especially in infants. A proper diagnosis of these two conditions, besides other 
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possible conditions mimicking reflux, is crucial in order to target the treatment, 
avoiding the overuse of antacid drugs which currently represents a major source 
of concern. The clinical picture alone is frequently nonspecific and does not allow, 
except in older children and adolescents, to detect the actual need for acid suppres-
sive medications. Therefore, instrumental diagnostic testing, such as esophageal 
combined multiple intraluminal impedance and pH monitoring and upper gastro-
intestinal endoscopy, are often requested [3].
The typical presentation of GERD includes the following symptoms: recurrent 
regurgitation, vomiting, weight loss or poor weight gain, excessive crying and irri-
tability in infants, heartburn or chest pain, ruminative behavior, hematemesis, and 
dysphagia. Besides these esophageal symptoms, there is a set of extra-esophageal 
symptoms, mainly respiratory, which may occur along with typical symptoms or 
may represent the only clinical picture of GERD: odynophagia, wheezing, stridor, 
cough, hoarseness, dental erosions, and apnea/apparent life-threatening events 
(ALTEs). Moreover, GERD may underlie other signs or conditions, such as impaired 
quality of life, food refusal, persisting hiccups, abnormal posturing/Sandifer’s 
syndrome, anemia, and bradycardia. Finally, esophagitis, Barrett’s esophagus, and 
esophageal adenocarcinoma are possible acknowledged and worrisome long-term 
outcomes, especially when GERD is undiagnosed or untreated [3].
As already reported, all the above-mentioned signs and symptoms are variously 
prevalent and relevant in the different pediatric age groups. Therefore, GERD clinical 
pictures of infants, children, and adolescents will be treated in separate paragraphs.
2. Clinical picture of physiologic GER and GERD in infants
Regurgitation and vomiting are very frequent in healthy infants, mostly during 
the first months of life. About 70% of healthy infants physiologically regurgitate 
several times per day, and in about 95% of them, symptoms disappear without 
intervention by 12–14 months of age [4, 5]. The term “happy spitter” has been used 
to identify these patients, in order to highlight the benignity of such condition. 
Infants regurgitate more frequently than adults due to the large liquid volume intake, 
the prolonged horizontal position of infants, and the limited capacity of both the 
stomach and esophagus [6]. Irritability and excessive crying are also very frequent in 
infants and may present along with regurgitation and vomiting. Therefore, neither 
regurgitation and vomiting nor irritability and excessive crying, regardless of their 
severity extent and their extent, are sufficient to diagnose GERD. GERD should be 
suspected in infants with these symptoms, but none of the symptoms are specific to 
GERD alone. The major role of history and physical examination in the evaluation 
of purported GERD is to rule out other more worrisome disorders that present with 
similar symptoms (especially vomiting) and to identify possible complications of 
GERD. The vast majority of spitting and crying infants suffer from physiologic GER 
(also called infant regurgitation), a benign condition with an excellent prognosis, 
needing no intervention except for parental education and anticipatory guidance, and 
possible changes on feeding composition. Overfeeding exacerbates recurrent regurgi-
tation [6]. Thickened or anti-regurgitation formulas decrease overt regurgitation [7].
Although reflux does occur physiologically in most infants, clinicians should 
be aware that there is a continuum between physiologic GER and GERD leading to 
significant symptoms, signs, and complications. Therefore, a small proportion of 
symptomatic infants may deserve an instrumental diagnostic assessment for GERD 
or other GERD-mimicking diseases. To help identify this subgroup of infants, 
the latest international GER guidelines drafted a list of warning signals requiring 
investigations in infants with regurgitation or vomiting (Table 1).
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3. Clinical picture of GERD in young children
Whether persisting from infancy or of new onset, regurgitation and vomiting 
are less common in children older than 18 months of age and deserve an instrumen-
tal evaluation to diagnose possible GERD or to rule out alternative diagnosis [2]. 
Besides regurgitation and vomiting, GERD may present in children with many 
Gastrointestinal bleeding
Hematemesis
Hematochezia
Bilious vomiting
Consistently forceful vomiting
Onset of vomiting after 6 months of life
Failure to thrive
Diarrhea
Constipation
Fever
Lethargy
Hepatosplenomegaly
Bulging fontanelle
Seizures
Macro/microcephaly
Abdominal tenderness or distension
Documented or suspected genetic/metabolic syndrome
Table 1. 
Warning signals requiring investigation in infants with regurgitation or vomiting.
Gastrointestinal obstruction
Pyloric stenosis
Malrotation with intermittent volvulus
Intestinal duplication
Hirschsprung disease
Antral/duodenal web
Foreign body
Incarcerated hernia
Other gastrointestinal disorders
Achalasia
Gastroparesis
Gastroenteritis
Peptic ulcer
Eosinophilic esophagitis/gastroenteritis
Food allergy
Inflammatory bowel disease
Pancreatitis
Appendicitis
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other signs or symptoms, the most frequent of which are heartburn, food refusal, 
dysphagia, feeding or sleeping disturbances, failure to thrive, persisting hiccups, 
impaired quality of life, and dental erosions. Respiratory symptoms, such as chronic 
cough, wheezing, hoarseness, laryngitis, chronic asthma, aspiration pneumonia, 
ear problems, and sinusitis, are atypical symptoms possibly associated with 
GERD. Nevertheless, the paucity of clinical studies, varying disease definitions, 
and small sample sizes do not allow to draw firm conclusions about their association 
with reflux [8].
According to the latest international pediatric guidelines, subjective reflux 
symptom description is unreliable in children younger than 8 to 12 years of age, 
and many of the purported symptoms of GERD in children are nonspecific [9–11]. 
Infectious
Sepsis
Meningitis
Urinary tract infection
Pneumonia
Otitis media
Hepatitis
Metabolic/endocrine
Galactosemia
Hereditary fructose intolerance
Urea cycle defects
Amino and organic acidemias
Congenital adrenal hyperplasia
Renal
Obstructive uropathy
Renal insufficiency
Toxic
Lead
Iron
Vitamins A and D
Medications—ipecac, digoxin, theophylline, etc.
Cardiac
Congestive heart failure
Vascular ring
Others
Pediatric falsification disorder (Munchausen syndrome by proxy)
Child neglect or abuse
Self-induced vomiting
Cyclic vomiting syndrome
Autonomic dysfunction
Table 2. 
Differential diagnosis of vomiting in infants and children.
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Therefore, a clinical diagnosis based on a history of heartburn cannot be inferred 
since these individuals cannot reliably communicate the quality and quantity 
of their symptoms [12–16]. GERD testing mainly include esophageal pH/MII, 
upper GI endoscopy, and barium upper GI series. The diagnosis of GERD has to 
be inferred when tests show excessive frequency or duration of reflux episodes, 
esophagitis, or a clear association of symptoms and signs with reflux episodes in the 
absence of alternative diagnose (Table 2).
4. Clinical picture of GERD in older children and adolescents
In older children and adolescents’ heartburn, regurgitation and chest pain are the 
specific symptoms of GERD. According to experts’ opinions, in this age group, the 
description and localization of these symptoms are a reliable indicator for GERD, and 
an acid suppressive trial may be empirically started, regardless of an objective evalu-
ation of reflux. This approach is mainly driven from adult studies [17, 18]. Along with 
heartburn and chest pain, other symptoms and signs may occur in older children and 
adolescents, such as regurgitation, epigastric pain, food refusal, dysphagia, impaired 
quality of life, sleeping disturbances, anorexia, and dental erosions. Moreover, 
likewise infants and younger children, even older children and adolescents, may 
experience respiratory symptoms as the only manifestation of GERD [3].
Several studies report a significant degree of overlap between GERD and 
functional dyspepsia (FD) [19, 20]. According to the Rome diagnostic criteria for 
pediatric functional gastrointestinal disorders, FD is defined as a “persistent or 
recurrent pain or discomfort in the upper abdomen, most often aggravated by meal 
ingestion, not relieved by defecation or associated with the onset of a change in 
stool frequency or stool form (i.e., not irritable bowel syndrome) when no physical 
or organic cause for the symptom is identified with conventional testing” [21].
Clinicians should careful approach upper GI symptoms, being aware that the cur-
rent literature on the overlap between GERD and FD is affected by considerable hetero-
geneity in terms of the criteria and diagnostic procedures used to assess both conditions. 
To exclude GERD, patients must undergo upper digestive endoscopy, pH monitoring, 
and/or an empiric acid-suppressive trial. A lack of correspondence between symptoms 
and reflux episodes, together with normal acid exposure in the distal esophagus, would 
suggest a diagnosis of FD. Finally, clinicians should also be aware that other causes of 
heartburn-like chest pain including respiratory, cardiac, musculoskeletal, medication-
induced, or infectious etiologies should be considered besides GERD.
5. Overview on GERD and respiratory symptoms
As abovementioned, GERD may also underlie respiratory symptoms, such as 
chronic cough, wheezing, stridor, odynophagia, and hoarseness. Although the role 
of GERD in the pathogenesis of respiratory symptoms in adults is widely accepted 
[22], in children there is less evidence to support this relationship [23, 24]. Several 
pathogenetic mechanisms have been proposed to explain the link between GERD 
and respiratory symptoms, including aspiration of acid gastric contents into the 
upper airways, vagal reflex induced by the presence of acid in the esophageal 
lumen, and sensitization of the central cough reflex [2, 25].
Recent advances in the pathogenesis of reflux-induced respiratory symptoms 
have followed the introduction in clinical practice of MII-pH, which is available for 
pediatric use since 2002 [26]. Combined esophageal pH and impedance monitor-
ing offer several advantages over a standard pH assessment, including the ability 
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of detecting non-acid reflux events, determining the height and composition of 
the refluxate (liquid, gas, or mixed), recognizing swallows from authentic reflux 
episodes, assessing the bolus clearance time, and measuring symptom associa-
tion with reflux (symptom association probability, SAP) even while the patient is 
assuming acid-suppressive medications [27]. Thanks to pH-impedance studies, 
several authors have recently highlighted the role of weakly acid and non-acid 
reflux [28–35]. Furthermore, a recent review reported that a significant percent-
age of patients with GERD-related respiratory symptoms do not improve despite 
an aggressive acid-suppressive therapy [36], thus supporting the hypothesis that 
respiratory symptoms are less related to acidity than GI symptoms.
In conclusion, the analysis of the medical literature concerning the relation-
ship between GERD and respiratory symptoms highlights a large body of evidence 
often discordant or conflicting, rarely allowing to draw firm conclusions to be 
used in clinical practice. Over the next years, the use of pH-impedance, combined 
with manometry or with cardiorespiratory monitoring, in longitudinal, placebo-
controlled, double-blind clinical trials, will help in clarifying the main pathophysi-
ological aspects that link GER and respiratory system, providing the clinician with 
fundamental scientific basis for diagnostic and therapeutic choices.
6. Management of physiologic GER
In newborns and infants, TLESRs are physiological events. Further consider-
ing the physiologic poorer tone of the lower esophageal sphincter, the frequency 
of GER events is commonly much higher compared to the other ages of life. Thus, 
uncomplicated GER in otherwise healthy infants is classified as physiologic or func-
tional GER. This condition tends to resolve spontaneously in 95% of infants within 
12–14 months of life [37, 38]. According to the current international guidelines, 
infants with functional GER should not receive pharmacological treatment, despite 
symptoms may cause significant distress to both infants and parents [2]. The most 
common symptoms associated with GER in the first year of life are regurgitation, 
vomiting, irritability, cough, and food refusal [39–42]. When physiologic GER is 
clinically suspected in healthy, thriving infants, parental education, reassurance, 
and anticipatory guidance are always required and usually sufficient [2].
6.1 Feeding changes in infants
Cow’s milk allergy: Infants with cow’s milk protein allergy may present with 
vomiting and regurgitation as well as infants with GER. In order to avoid possible 
misdiagnoses, formula-fed infants with regurgitation and vomiting could benefit 
of a 4-week trial with hydrolyzed milk or amino acid formula [43, 44]. Breast-fed 
infants as well may be affected by cow’s milk protein allergy since a few proteins 
pass into the human breast milk. Therefore, an exclusion of cow’s milk proteins 
from maternal diet should be considered [45–47].
Overfeeding: Although exact numbers are unknown, overfeeding has recently 
been thought to be a prominent cause of GER because the ingested volume is rela-
tively large compared to the size of the stomach in infants. Large-volume feeds can 
promote regurgitation in infants due to gastric distention and increase in TLESR 
frequency [48]. Restricting volume, however, can result in insufficient energy 
intake. Thus, increasing the caloric concentration of the feedings while decreasing 
the total volume of the feedings may decrease GER [2].
Thickening feeds: Several studies have demonstrated the efficacy of thickened 
formula in reduction of reflux events in infants with GER. A thickened formula 
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was recently tested in premature neonates with apnea. The primary outcome was 
assessed through multichannel intraluminal impedance, reporting a significant 
decrease of only acid reflux episodes, while apneic episodes and non-acid GER 
indexes were not significantly altered [49–51]. The efficacy of thickened formula 
was demonstrated both on typical and atypical reflux symptoms [52–55]. Despite 
thickened feeds are currently increasingly being used to treat infants with GER 
[56], it has been debated that thickened formula increases the caloric intake, thus 
predisposing infants to later obesity [51, 53, 56–58]. Conversely, infants fed with 
formula thickened with carob bean gum were reported having a comparable weight 
increase to the control group [54]. Similar results were with a soy fiber-thickened 
formula [58]. Furthermore, the fermentation of thickening agents has been 
reported to cause side effects such as abdominal pain and diarrhea [42]. Further, 
well-designed clinical trial on these possible side effects are needed in order to 
evaluate their true relevance.
6.2 Positioning therapy for infants
Positioning of the body may have an impact on the incidence of GER epi-
sodes. Therefore, among the conservative measures to manage infantile GER, 
the current NASPGHAN-ESPGHAN guidelines include positioning strategies. 
Different positionings have been so far evaluated: semisupine, prone, supine 
and flat, supine with head elevated, and left-side down and right-side down 
position [59–66]. Infants with GER were shown having a longer exposure to gas-
troesophageal reflux in semisupine position, with an infant seat, than in prone 
position. Therefore, semisupine position is strongly discouraged, especially for 
infants younger than 6 months of age. The prone position reduces the reflux epi-
sodes significantly more than the other positions. However, the increased risk of 
a sudden infant death syndrome (SIDS) shifts the prone position in a negative 
cost/benefit ratio. Currently, the prone position is advisable only in infants with 
demonstrated airway disorders, in which the risk of death from GERD is higher 
than that from SIDS. Conversely, the prone position may be suggested for all 
infants in the early postprandial period when they are still awake or in children 
older than 1 year of age [2].
6.3 PPI abuse in infants
The number of PPI prescriptions for infants has increased manifold over the last 
years, despite the absence of evidence for acid-related disorders in the majority [66, 
67]. This dramatic increase in PPIs’ prescribing patterns has raised concerns related 
to their appropriate use and associated costs [68]. Although irritable infants are 
frequently empirically treated with PPIs as the reflux esophagitis is believed to be 
the cause of crying, there is no evidence supporting the usefulness of PPIs, neither 
as a diagnostic test nor as a treatment strategy in this age group. Double-blind 
randomized placebo-controlled trials of PPI efficacy in infants with GER symptoms 
showed that PPIs and placebo produced similar improvement in crying, despite the 
finding that acid suppression occurred only in the PPI group [6, 69]. In the largest 
double-blind randomized placebo-controlled trial of PPIs in infants with symptoms 
purported to be GERD-related, response rates in those treated with lansoprazole or 
placebo for 4 weeks were identical (54%) [70]. Therefore, no placebo-controlled 
treatment trial, in which enrollment was based on “typical” GERD symptoms, 
has demonstrated symptom improvement in infants. Thus, in accordance to the 
ESPGHAN-NASPGHAN international guidelines, we believe that a serious effort to 
curtail PPI empiric use in infant is firmly required.
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7. Treatment options for GERD
GERD management in children includes lifestyle changes, pharmacologic 
therapy, and surgery. Lifestyle changes which may contribute to prevent and 
improve reflux symptoms in infants have already been discussed in the previous 
sections. In children and adolescents, lifestyle changes include modification of diet 
and sleeping position, weight reduction, and smoking cessation [2, 71]. Although 
usually sufficient to manage physiologic GER, lifestyle changes alone are not effec-
tive in the treatment of GERD, which must include pharmacologic therapies and 
possible surgical intervention for severe, unresponsive cases.
The major pharmacologic agents currently used for treating GERD in children 
are gastric acid-buffering agents, mucosal surface barriers, and gastric antisecre-
tory agents. Since the withdrawal of cisapride from commercial availability in most 
countries, prokinetic agents have been less frequently used, although domperidone 
is commercially available in Canada and Europe. Pediatric studies comparing 
pharmacologic agents for GERD have been impaired by small sample size, absence 
of controls, and use of unreliable endpoints. Therefore, most studies investigating 
effectiveness and safety of GERD drugs have been performed in adults, and their 
applicability to children of all ages is uncertain.
7.1 Histamine-2 receptor antagonists
Histamine-2 receptor antagonists (H2RAs) inhibit histamine-2 receptors on 
gastric parietal cells, thus decreasing acid secretion. H2RAs currently available in 
most countries are cimetidine, ranitidine, famotidine, and nizatidine. These four 
drugs have similar spectra of activity, side effects, and clinical indications and are 
extremely well tolerated by patients [72–79]. However, the efficacy of H2RAs in 
achieving mucosal healing is much greater in mild than in severe esophagitis [80]. 
Extrapolation of the results of a large number of adult studies to older children and 
adolescents suggests that H2RAs may be used in these patients for the treatment 
of GERD symptoms and for healing esophagitis, although H2RAs are less effective 
than PPIs for both symptom relief and healing of esophagitis [77, 81, 82]. The fairly 
rapid tachyphylaxis that develops with H2RAs is a major drawback to their chronic 
use. The occurrence of tachyphylaxis, or a decrease of the response, to intravenous 
ranitidine and the escape from its acid-suppressive effect have been observed after 
6 weeks [83], and tolerance to oral H2RAs in adults is well recognized [84, 85]. In 
some infants, H2RA therapy causes irritability, head banging, headache, somno-
lence, and other side effects that, if interpreted as persistent symptoms of GERD, 
could result in an inappropriate increase in dosage [79]. H2RAs, particularly cimeti-
dine, are associated with an increased risk of liver disease [86, 87] and cimetidine 
with gynecomastia [88].
7.2 Proton pump inhibitors
PPIs act by blocking Na+–K+-ATPase, the final common pathway of parietal cell 
acid secretion, often called the proton pump, thus inhibiting acid secretion. Studies 
in adults have shown that PPIs produce higher and faster healing rates for erosive 
esophagitis than H2Ras, largely because of their ability to maintain intragastric pH 
at or above 4 for longer periods and to inhibit meal-induced acid secretion [89]. 
Moreover, the strong suppression of acid secretion by PPIs also results in decrease 
of 24-h intragastric volumes, thereby facilitating gastric emptying and decreasing 
volume reflux [90]. To date, PPIs approved for use in children in North America 
are omeprazole, lansoprazole, esomeprazole, pantoprazole, and rabeprazole. No 
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PPI has been approved for use in infants younger than 1 year of age. Most studies of 
PPIs in children are open-label and uncontrolled [91, 92]. In children, as in adults, 
PPIs are highly efficacious for the treatment of GERD symptoms and the healing of 
erosive disease. PPIs have greater efficacy than H2RAs. Young children may require 
higher per kilogram doses to obtain the same acid-blocking effect [93–96].
7.3 Prokinetic agents
Although the role of delayed gastric emptying in the pathogenesis of GERD has 
never been clarified and remains controversial, prokinetic agents have been used 
as first-choice treatment for reflux symptoms in children for many years. The most 
well-known prokinetic drug is cisapride, widely prescribed until 2000, when it 
was withdrawn due to cardiac toxicity which increased the risk of sudden death 
[97]. Currently, other prokinetics such as domperidone and metoclopramide are 
still commonly prescribed. Nevertheless, neither have robust evidence to support 
their use in children with GERD [98–100]. Baclofen is a gamma-amino-butyric-acid 
(GABA) receptor agonist which has been shown to reduce both acid and non-acid 
refluxes in adults, probably by inhibiting the transient relaxations of the lower 
esophageal sphincters (TLESRs) [101]. In children, baclofen was shown to acceler-
ate gastric emptying for 2 h after administration, decreasing the frequency of 
emesis [102, 103]. Despite its promising effects, many side effects, such as dyspeptic 
symptoms, drowsiness, dizziness, and seizures, preclude its routine use [104]. In 
conclusion, there is insufficient evidence to justify the routine use of cisapride, 
metoclopramide, domperidone, or baclofen for GERD.
7.4 Alginates and antacids
Alginates and antacids are commonly combined in the same product and are 
widely used by adult patients to treat reflux symptoms. Antacids act by directly 
buffering gastric contents, thereby reducing heartburn. There is little evidence 
for the use of antacids in pediatric age [105, 106]. Conversely, alginates have been 
studied to a greater extent in children. Alginates precipitate in the stomach to form 
a low-density but viscous gel that forms a foam that floats on the surface of gastric 
content and can preferentially enter the esophagus instead of gastric content during 
reflux episodes [107]. Studies performed both in infants and children showed a 
significant reduction in the height of reflux episodes, along with an improvement 
of symptomatic scores [108–113]. On-demand use of antacids and alginates may 
provide prompt relief from reflux symptoms in children and adolescents [114]. 
Nevertheless, although alginates seem to have a good safety profile, antacids have 
possible adverse effects, such as increased serum levels of aluminum, magnesium, 
or calcium, which represent a major drawback to their long-term use [113, 115, 116].
7.5 Surgical therapy
Surgical treatment represents the last option for GERD management. When 
and which children could likely benefit from anti-reflux surgery (ARS) has never 
yet been elucidated. Currently, surgery should be considered for children with 
confirmed GERD who have failed optimal medical therapy, who are dependent on 
medical therapy over a long period of time, who are significantly nonadherent with 
medical therapy, or who have life-threatening complications [2]. Medical literature 
on surgical therapy in children with GERD mainly consists of retrospective case 
series in which details on GERD diagnosis and on previous medical therapy are par-
tially lacking, making it difficult to evaluate the indications for and the outcomes of 
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surgery [117–119]. Moreover, most surgical series include children with underlying 
conditions predisposing to the most severe GERD, such as neurological impairment, 
thereby confounding efforts to determine the benefits versus risks of surgical anti-
reflux procedures in specific patient populations. Nevertheless, according to the 
available data, ARS in children shows a good overall success rate (median 86%) in 
terms of complete relief of symptoms, and its outcome does not seem to be signifi-
cantly influenced by different surgical techniques [120]. Gastric fundoplication 
is the most commonly performed intervention. Different types of fundoplication 
have been developed, according to Nissen (360° fundic wrap around the esophagus) 
and Thal and Toupet (both partial wraps). Traditionally, these procedures were 
performed open, whereas in most centers, laparoscopic fundoplications are now 
preferred. Nevertheless, a recent pediatric trial showed that open and laparoscopic 
fundoplications provide similar control of reflux and quality of life at follow-up, 
although the latter is associated with reduced incidence of retching persisting over a 
4-year period [120–122].
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